(Des-Leu9)-Kinetensin peptide

(Des-Leu9)-Kinetensin peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

IARRHPYF

H-Ile-Ala-Arg-Arg-His-Pro-Tyr-Phe-OH

8

98.1%

C₅₀H₇₄N₁₆O₁₀

1059.24

Synthetic

Powder

This peptide, also called histamine-releasing peptide (HRP), was originally isolated from incubates of mammalian albumins with acid proteases, but is also generated by stimulated rat mast cells in the presence of BSA. HRP is able to release histamine from isolated mast cells and to increase cutaneous vascular permeability. Furthermore, the peptide is chemotactic to human and rat neutrophils.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• R.E.Carraway et al., J. Immunol., 143, 1680 (1989)
• D.E.Cochrane et al., Peptides, 14, 117 (1993)

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.